Raffles Medical Group Ltd (RAFLF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Raffles Medical Group Ltd (RAFLF) trades at $0.67 with AI Score 54/100 (Grade B). Raffles Medical Group Ltd provides integrated private healthcare services across Singapore, Greater China, and Southeast Asia. Market cap: $1.23B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for RAFLF: RAFLF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RAFLF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
RAFLF: 1/3 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Raffles Medical Group Ltd (RAFLF) Healthcare & Pipeline Overview
Raffles Medical Group Ltd, a Singapore-based integrated healthcare provider, operates across Southeast Asia and Greater China, offering a comprehensive suite of medical services through its hospitals and clinics. With a focus on patient-centric care and a strong presence in key markets, the company aims to capitalize on the growing demand for quality healthcare services in the region.
What Is the Investment Thesis for RAFLF?
Raffles Medical Group presents an investment opportunity based on its established presence in the growing Asian healthcare market. With a P/E ratio of 36.0 and a profit margin of 8.3%, the company demonstrates stable profitability. Key growth drivers include expanding its network of clinics and hospitals in Greater China and Southeast Asia, capitalizing on the increasing demand for private healthcare services. The company's dividend yield of 2.48% provides a steady income stream for investors. However, potential risks include increased competition from other healthcare providers and regulatory changes in the countries where it operates. The company's beta of 0.20 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
RAFLF Key Highlights
Market capitalization of $1.23B, reflecting its significant presence in the healthcare sector.
- P/E ratio of 36.0, indicating a premium valuation compared to some peers, potentially reflecting investor expectations for future growth.
- Profit margin of 8.3%, demonstrating its ability to generate profits from its operations.
- Gross margin of 45.6%, showcasing efficient cost management in delivering healthcare services.
- Dividend yield of 2.48%, providing a steady income stream for investors.
Who Are RAFLF's Competitors?
RAFLF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| EXETF Extendicare Inc. | $22.21 | -2.72% | $2.11B | 54 |
| KSPHF Kissei Pharmaceutical Co., Ltd. | $25.77 | +0.00% | $1.07B | 50 |
| LTGHF Life Healthcare Group Holdings Limited | $0.69 | +0.00% | $987M | 44 |
| LWSCF Sienna Senior Living Inc. | $15.60 | -0.95% | $1.55B | 49 |
| MRCHF H.U. Group Holdings, Inc. | $22.95 | +0.00% | $1.27B | 49 |
| USPH U.S. Physical Therapy, Inc. | $78.00 | -1.53% | $1.19B | 60 |
| AMN AMN Healthcare Services, Inc. | $34.79 | -1.50% | $1.35B | 91 |
| PNTG The Pennant Group, Inc. | $39.00 | -0.36% | $1.36B | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RAFLF's Key Strengths?
Strong brand reputation and established presence in Singapore.
- Integrated healthcare model with a comprehensive range of services.
- Extensive network of clinics and hospitals across the region.
- Experienced management team with a proven track record.
What Are RAFLF's Weaknesses?
Limited presence in some key markets, such as China.
- Reliance on the Singapore market for a significant portion of revenue.
- Exposure to regulatory changes and healthcare reforms.
- Competition from other established healthcare providers.
What Could Drive RAFLF Stock Higher?
Expansion of clinic network in Southeast Asia, increasing patient access and revenue.
- Development and launch of new specialized medical services, attracting more patients.
- Potential partnerships with insurance companies to expand coverage and patient base.
- Leveraging technology to improve operational efficiency and patient experience.
- Increasing demand for private healthcare services in Asia due to rising affluence.
What Are the Key Risks for RAFLF?
Rich valuation — a P/E of 36.0 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Increased competition from other healthcare providers in the region.
- Regulatory changes and healthcare reforms impacting pricing and reimbursement.
- Economic downturns and reduced healthcare spending affecting revenue.
- Outbreaks of infectious diseases disrupting operations and patient flow.
- Fluctuations in currency exchange rates impacting financial performance.
What Are the Growth Opportunities for RAFLF?
- Expansion in Greater China: Raffles Medical Group has the opportunity to expand its presence in Greater China, capitalizing on the growing demand for private healthcare services in the region. This includes establishing new clinics and hospitals, as well as partnering with local healthcare providers. The Chinese healthcare market is one of the largest and fastest-growing in the world, offering significant growth potential for Raffles Medical Group. Timeline: Ongoing.
- Strengthening presence in Southeast Asia: Raffles Medical Group can further strengthen its presence in Southeast Asia by expanding its network of clinics and hospitals in key markets such as Vietnam, Cambodia, and Indonesia. The region is experiencing rapid economic growth and increasing demand for quality healthcare services, creating opportunities for Raffles Medical Group to expand its market share. Timeline: Ongoing.
- Development of specialized medical services: Raffles Medical Group can develop and expand its specialized medical services, such as cancer treatment, cardiology, and orthopedics, to attract more patients and increase revenue. This includes investing in advanced medical equipment and technologies, as well as recruiting top medical specialists. The demand for specialized medical services is growing rapidly, driven by an aging population and increasing prevalence of chronic diseases. Timeline: Ongoing.
- Leveraging technology and innovation: Raffles Medical Group can leverage technology and innovation to improve its operational efficiency, enhance patient experience, and develop new healthcare solutions. This includes implementing electronic health records, telemedicine platforms, and artificial intelligence-powered diagnostic tools. The use of technology can help Raffles Medical Group to reduce costs, improve quality of care, and expand its reach to new markets. Timeline: Ongoing.
- Strategic partnerships and acquisitions: Raffles Medical Group can pursue strategic partnerships and acquisitions to expand its service offerings, enter new markets, and gain access to new technologies. This includes partnering with other healthcare providers, technology companies, and research institutions. Strategic partnerships and acquisitions can help Raffles Medical Group to accelerate its growth and strengthen its competitive position. Timeline: Ongoing.
What Are RAFLF's Competitive Advantages?
- Established brand reputation and trust in the Singapore healthcare market.
- Integrated healthcare model with a comprehensive range of services.
- Extensive network of clinics and hospitals across Singapore and the region.
- Strong relationships with corporate clients and insurance companies.
- Focus on quality and patient-centric care.
What Does RAFLF Do?
Founded in 1976 and headquartered in Singapore, Raffles Medical Group Ltd has grown into a leading integrated private healthcare provider in the region. The company's operations span across Singapore, Greater China, Vietnam, Cambodia, and Japan, with a focus on delivering comprehensive and patient-centric medical services. Raffles Medical Group operates through three primary segments: Healthcare Services, Hospital Services, and Investment Holdings. Its flagship facility, Raffles Hospital, is a tertiary care hospital offering a wide range of specialist services, including cancer treatment, women's and children's care, cardiology, orthopedics, and traditional Chinese medicine. In addition to hospital services, Raffles Medical Group operates a network of clinics providing family medicine, health screening, and specialist consultations. The company also engages in trading pharmaceutical and nutraceutical products, providing advisory and consultancy services, and developing IT solutions for healthcare management. Raffles Medical Group Ltd operates as a subsidiary of Raffles Medical Holdings Pte. Ltd.
What Products and Services Does RAFLF Offer?
- Operates Raffles Hospital, a tertiary care hospital in Singapore.
- Manages a network of family medicine and specialist clinics.
- Provides health screening and vaccination services.
- Offers a range of specialist medical services, including cardiology, oncology, and orthopedics.
- Trades in pharmaceutical and nutraceutical products.
- Provides advisory and consultancy services related to healthcare management.
- Develops IT solutions for healthcare providers.
- Engages in research and experimental development in biotechnology and life sciences.
How Does RAFLF Make Money?
- Generates revenue from hospital services, including inpatient and outpatient care.
- Earns fees from medical consultations, health screenings, and vaccinations.
- Sells pharmaceutical and nutraceutical products through its clinics and hospitals.
- Provides advisory and consultancy services to other healthcare providers.
- Develops and licenses IT solutions for healthcare management.
What Industry Does RAFLF Operate In?
Raffles Medical Group operates within the rapidly growing Asian healthcare market, driven by increasing affluence, aging populations, and rising awareness of healthcare needs. The industry is characterized by increasing demand for quality private healthcare services, creating opportunities for established players like Raffles Medical Group. Competition includes other private hospitals and clinics, as well as public healthcare providers. The company's integrated healthcare model and regional presence provide a competitive advantage in capturing market share.
Who Are RAFLF's Key Customers?
- Individuals seeking medical care and health screening services.
- Corporate clients seeking occupational health and wellness programs for their employees.
- Insurance companies covering medical expenses for their policyholders.
- Government agencies seeking healthcare services for the public.
- Other healthcare providers seeking advisory and consultancy services.
Raffles Medical Group Ltd Financial Trajectory
Raffles Medical Group Ltd (RAFLF) reported $176.6M in revenue for Q2 2026, reflecting 0.0% growth compared to the prior quarter. The company recorded net income of $14.5M, with diluted EPS of $0.01. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, RAFLF averaged $0.01 in diluted EPS.
Company Profile
Raffles Medical Group Ltd operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Singapore, SG. The company is led by CEO Choon Yong Loo. RAFLF has traded publicly since 2009.
How Raffles Medical Group Ltd Is Valued
Raffles Medical Group Ltd carries a market capitalization of $1.23B, placing it in the small-cap category. Relative to its peer group, RAFLF's quantitative score of 54/100 is roughly in line with the peer average of 49/100.
Key Financial Metrics
Return on equity for Raffles Medical Group Ltd stands at 4.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.4%, showing how much profit it generates from its asset base. RAFLF trades at a trailing price-to-earnings ratio of 36.03, above the Healthcare sector average of ~23x. Its free cash flow yield is 4.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.31 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.8%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Raffles Medical Group Ltd's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 4.17 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
Raffles Medical Group Ltd has beaten Wall Street's EPS estimate in 4 of its last 4 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 46.5% above estimates on average.
Forward Outlook
Wall Street analysts project Raffles Medical Group Ltd revenue of about $742.5M for fiscal 2026, with EPS near $0.03. The estimate reflects 7 contributing analysts.
RAFLF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong brand reputation and established presence in Singapore.
- Integrated healthcare model with a comprehensive range of services.
- Extensive network of clinics and hospitals across the region.
- Experienced management team with a proven track record.
Bear Case
- Limited presence in some key markets, such as China.
- Reliance on the Singapore market for a significant portion of revenue.
- Exposure to regulatory changes and healthcare reforms.
- Competition from other established healthcare providers.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $177M | $15M | $0.01 |
| Q1 2026 | $177M | $15M | $0.01 |
| Q4 2025 | $194M | $19M | $0.01 |
| Q3 2025 | $194M | $19M | $0.01 |
Based on FMP financials and quantitative analysis
RAFLF Latest News
-
Neurophet Supplies 'Neurophet AQUA' to Raffles Medical in Singapore
Yahoo! Finance: RAFLF News · Jul 2, 2026
RAFLF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RAFLF.
Price Targets
Wall Street price target analysis for RAFLF.
RAFLF MoonshotScore
What does this score mean?
The MoonshotScore rates RAFLF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Choon Yong Loo
Chairman and CEO
Choon Yong Loo serves as the Chairman and CEO of Raffles Medical Group. He has been with the company for several years, guiding its strategic direction and expansion. Dr. Loo is a medical doctor by training, bringing a clinical perspective to his leadership role. He has been instrumental in driving the company's growth and establishing its reputation as a leading healthcare provider in the region. His expertise lies in healthcare management, strategic planning, and business development.
Track Record: Under Dr. Loo's leadership, Raffles Medical Group has expanded its network of hospitals and clinics, both in Singapore and across the region. He has overseen the development of new medical services and technologies, as well as the implementation of innovative healthcare solutions. Dr. Loo has also played a key role in forging strategic partnerships and acquisitions, contributing to the company's growth and market position.
RAFLF OTC Market Information
The OTC Other tier, where RAFLF trades, represents securities that are not listed on a national exchange like the NYSE or NASDAQ. These securities often belong to companies with limited operating history, smaller market capitalization, or those that do not meet the listing requirements of the major exchanges. Companies on the OTC Other tier may have limited regulatory oversight and reporting requirements compared to exchange-listed companies, leading to increased risks for investors. This tier is considered the most speculative segment of the OTC market, as it includes companies with the least amount of publicly available information.
- OTC Tier: OTC Other
- Limited regulatory oversight and reporting requirements compared to exchange-listed companies.
- Potential for information asymmetry due to limited publicly available information.
- Higher price volatility due to lower trading volume and liquidity.
- Increased risk of fraud or manipulation due to less stringent listing standards.
- Difficulty in obtaining accurate and timely financial information.
- Verify the company's registration and legal status.
- Obtain and review the company's financial statements, if available.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Understand the OTC market and its associated risks.
- Consult with a qualified financial advisor.
- Established presence in the healthcare sector with a long operating history.
- Reputable management team with experience in the healthcare industry.
- Positive customer reviews and testimonials.
- Partnerships with established healthcare providers and organizations.
- Compliance with relevant healthcare regulations and standards.
What Investors Ask About Raffles Medical Group Ltd (RAFLF) — Healthcare
What does the AI Score mean for RAFLF?
RAFLF holds an AI Score of 54/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Raffles Medical Group Ltd provides integrated private healthcare services across Singapore, Greater China, and Southeast Asia. The company operates hospitals, clinics, and offers a range of medical …
What does Raffles Medical Group Ltd do?
Raffles Medical Group Ltd operates as an integrated healthcare provider, primarily in Singapore, Greater China, and Southeast Asia. The company provides a comprehensive range of medical services through its hospitals and clinics, including specialist care, family medicine, health screening, and emergency services. Raffles Medical Group also trades in pharmaceutical and nutraceutical products and develops IT solutions for healthcare management.
What are the main risks for RAFLF?
Raffles Medical Group faces several risks, including increased competition from other healthcare providers, regulatory changes and healthcare reforms impacting pricing and reimbursement, economic downturns and reduced healthcare spending, outbreaks of infectious diseases disrupting operations, and fluctuations in currency exchange rates impacting financial performance.
What are the key factors to evaluate for RAFLF?
Raffles Medical Group Ltd (RAFLF) holds an AI score of 54/100 (moderate). P/E: 36.0x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does RAFLF data refresh on this page?
RAFLF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RAFLF's recent stock price performance?
Raffles Medical Group Ltd (RAFLF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand reputation and established presence in Singapore. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RAFLF overvalued or undervalued right now?
Raffles Medical Group Ltd (RAFLF) trades at 36.0x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RAFLF before investing?
Before investing in Raffles Medical Group Ltd (RAFLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding RAFLF to a portfolio?
Key strength of Raffles Medical Group Ltd (RAFLF): Strong brand reputation and established presence in Singapore. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis pending for more comprehensive insights.